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Abstract 
Background: Airborne allergens can induce an immunological chronic disease characterized by airway hyper 
responsiveness and inflammation, mediated by exaggerated Th2 immune response. Allergen-specific immunother-
apy (AIT) is effective for treating this condition because it is able to modify its natural course by opposing the underly-
ing pathogenic mechanisms and determining immune suppression, immune deviation and tolerance. The rational 
for the present study was to investigate the possibility of improving allergoid-based IT in terms of efficacy and safety. 
Recently, 1α,25-dihydroxyvitamin D3 (VD3), the active metabolite of vitamin D3, was described to be a potent inducer 
of T regulatory cells and to be a good adjuvant in AIT settings.
Methods: We investigated whether the co-administration of VD3 could potentiate the effect of AIT even when added 
to a low dose of chemically-modified monomeric allergoid of Der p 2 (d2-OID), in a Derp p 2 (d2)-sensitized BALB/c 
mice model. Control groups where treated with sham, VD3 alone or d2-OID only.
Results: The d2-OID alone was not fully successful, as expected for a low dose. VD3 administration was associated 
with some valuable, although limited, changes in the immunological parameters in the lung. On the contrary, the 
VD3 adjuvated allergoid vaccine induced the most prominent reduction of airway eosinophilia and Th2 cytokines and 
concomitant increase of T regulatory cells and IL-10 in the lung and Der p 2-specific IgG2a in the serum.
Conclusions: The addition of VD3 to a conventional AIT protocol would allow the reduction of allergoid dose needed 
and therefore, the production costs. Moreover, beneficial immunomodulatory effects have been achieved by the oral 
administration which might favour the management of the therapy by the patients and their adherence, possibly 
enhancing the efficacy of the treatment.
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Background
One of the most reliable mechanisms explaining the 
desensitizing action of AIT (allergen immunotherapy) 
is based on its ability to induce tolerogenic dendritic 
cells (DC) characterized by an immature immunophe-
notype (iDC, DC0); these latter are crucial in favouring 
the differentiation of adaptive CD4+CD25+Fopx3+ T 
regulatory cells (Tregs) stemming from peripheral T-cells 
[1]. The Tregs have the property of inducing anergy of 
allergen-specific Th2 effector cells through the secreted 
inhibitory cytokine IL-10 [2]. In clinical settings, effective 
AIT has been also associated with increased production 
of allergen-specific IgG4 antibodies [3]: these are thought 
to play a protective role by acting as blocking antibodies 
(which compete with the allergen-specific IgE, thus pre-
venting the degranulation of effector cells) and by ham-
pering the IgE-mediated presentation of the allergen to 
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T cells [4]. Likewise, successful AIT was associated with 
an increase of IgG2a antibodies in mouse models of Der 
p 2 -induced allergic asthma [5, 6], although such ben-
eficial role of IgG is not generally proved in other mouse 
models.
Over the years, several scientific efforts aimed at 
enhancing the efficacy and safety of AIT. The biologically 
active form of vitamin D3 (VD3) seems a good adjuvant 
for AIT as for its ability of modulating the innate and 
adaptive immune response [7–9] and inhibit DCs differ-
entiation maintaining them in a persistent state of imma-
turity, through the down-regulation of co-stimulatory 
molecules and reduction of pro-inflammatory cytokines 
[10]; thus making them unable to activate alloreactive T 
cells [7]. VD3 is able to restore IL-10 secretion by Treg 
cells isolated from steroid-resistant asthmatics [11] and 
has the capacity to expand functional Tregs, able to sup-
press the Th2-driven response upon transfer in OVA-
sensitized asthmatic mice [12]. Furthermore, VD3 is able 
to expand in vitro PBMC-derived human Tregs (Foxp3hi) 
obtained from atopic allergic subjects [13].
The concept of using VD3 as a down modulator of aller-
gic diseases has been further explored in animal mod-
els. In OVA sensitized mice, the co-administration of 
VD3 plus OVA significantly inhibited the airway hyper-
responsiveness and potentiated the AIT effect by further 
reducing serum OVA-specific IgE level, airway eosino-
philia and Th2-related cytokines; the boosting effect of 
VD3 seems to be mediated by IL-10 and TGF-β, since the 
levels of these cytokines were elevated in the VD3-treated 
mice and the beneficial effect was abrogated in the pres-
ence of antibodies directed to these cytokines [14]. 
Moreover, VD3 supplementation confers durability of 
the beneficial effects of OVA-specific IT in VD3-deficient 
OVA-sensitized mice [15], suggesting the instauration of 
an effective tolerance.
In another study, VD3 was covalently linked to the 
major cat allergen Fel d 1 to be administered as desen-
sitizing treatment to allergic mice. The VD3-Fel d 1 vac-
cine, as well as the conventional one, induced serum 
allergen-specific IgE-to-IgG isotype switch and reduction 
of Th2 cytokines; interestingly, the VD3-containing vac-
cine was more potent in inhibiting the allergen-induced 
airway symptoms, especially the eosinophilic inflam-
mation [16]. The capacity to hold back the recruitment 
of eosinophils, possibly linked to the reduction of IL-5 
levels, was observed also in another experimental set-
ting [17]. VD3 has been tested in clinical settings too: 
in asthmatic children, VD3 administration significantly 
potentiates the AIT (subcutaneous) outcome, still pro-
moting the increase of Treg frequency and immuno-
suppressive IL-10 and TGF-β cytokines expression [18]; 
while in another study, in children with allergic rhinitis, 
VD3 supplementation combined with AIT (sublingual) 
was more effective in the reduction of nasal and asthma 
symptoms [19]. Interestingly enough, VD3 has been pro-
posed to be beneficial also in the setting of autoimmune 
disease patients affected by lupus through the decrease 
of the Th1-type immune response and Th1/Th2 ratio and 
increase in Treg [20]. Since VD3 can improve the effects 
of AIT, as widely demonstrated by the mentioned studies, 
its efficacy may be achieved also by reducing the vaccine 
doses. Such decrease of the amount of allergen in human 
vaccines would lower the cost of the therapy, considered 
an essential element for adherence. For this reason, the 
major purpose of the present study is to verify if a low 
dose of AIT associated to VD3 maintains similar effects 
to those of common AIT at usual doses, in the BALB/c 
mouse model of type I allergy towards Der p 2.
Methods
Animals
Specific pathogen free BALB/c mice (female, 8  weeks-
old, 20–25  g of weight) were purchased from Charles 
River (Milan, Italy). The animals were housed in plastic 
cages with absorbent bedding material and amusement 
tools and were maintained on a 12 h daylight cycle. Dur-
ing the experiment, the mice were fed with “Altromin R” 
containing 2.0 IU of VD3 per gram of food and 9.8 g/kg of 
calcium. Food and water were provided ad libitum.
Sensitization, challenge, and AIT protocol
Briefly, mice were sensitized with i.p. injections of 1  µg 
recombinant d2 adsorbed onto 2  mg Al(OH)3 (Lofarma, 
Milan, IT) in a total volume of 100 µl of pyrogen-free saline 
on days 0 and 14. Al(OH)3 served as an adjuvant to favor a 
Th2 response towards. The mice were challenged through 
i.p. injections with 1  µg recombinant d2 on day 37, and 
with aerosolised 1  % HDM extract in pyrogen-free saline 
to induce airway inflammation during and after the AIT 
period (days 27, 44, 60, 62, 64). The allergoid of the Der p 2 
antigen was used as the vaccine tool for AIT, characterized 
by reduced availability of IgE binding sites while preserving 
epitopes necessary for T cell recognition and for induction 
of non pathogenic IgG blocking antibodies [21–24].
The sensitized and challenged mice received 3  µg of 
d2-OID alone (group d2-OID) or in combination with 
120  ng of VD3 (group d2-OID +  VD3). The production 
and purification regarding all forms of allergen/allergoid 
and the assessment of the low dose to be used in AIT—
i.e. 3 µg—are fully described in the Additional file 1.
As controls, one group of sensitized mice was treated 
with 120 ng (group VD3) of VD3 alone, or saline (group 
Sham) following the same time schedule. The dose of VD3 
was chosen on the basis of literature data [17, 25]. For 
these experiments, the biologically active form of VD3, 
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1,25(OH)2VD3 (Sigma Aldrich, Milan, IT) was dissolved 
in 96  % ethanol and freshly diluted in d2-OID solution. 
Then, 48 h after the last aerosol challenge, blood, bron-
choalveolar lavage fluid (BALF), lung and spleen were 
harvested further analysis. The type of mice treatments 
and the time schedule were performed as described in 
the Additional file 1.
Determination of serum levels of d2‑specific antibodies
After 48  h from the last HDM aerosol challenge, blood 
was drawn from each mice via cardiac puncture. After 
blood coagulation had occurred, sera were stored at 
−20 °C until levels of d2-specific and total IgE and IgG2a 
were determined by enzyme-linked immunosorbed assay 
(ELISA). In brief, for d2-specific IgE titration, 96-wells 
microtiter plates (Maxisorp, Nunc) were coated with 
100 µl of recombinant d2 at 1 µg ml−1 in 0.1 M NaHCO3 
buffer (pH 9.5). After overnight incubation at 4  °C, the 
plates were washed and blocked with 2 % bovine serum 
albumin in PBS for 2  h at room temperature (RT). 
Diluted serum samples (1:100 for IgE and 1:500 for 
IgG2a) were incubated with the plate for 2 h, at RT. Next, 
after multiple washings, the wells were incubated for 2 h 
at RT with goat anti-mouse IgE isotype or IgG2a isotype 
(Bethyl laboratories, Montgomery, USA) diluited in 0.1 % 
bovine serum albumin (BSA) in PBS buffer (1: 1000 for 
IgE and 1:1000 for IgG2a). Rabbit anti-goat Ig-peroxidase 
(Bethyl) diluited in 0.1  % BSA in PBS buffer (1:10,000) 
was added for 1  h at RT. For color development, the 
chromogenic substrate TMB (Sigma-Aldrich) was added 
and, after an incubation of 15 min, the reaction stopped 
by adding 1 N H2SO4. The absorbance was measured at 
450 nm using the Lambda 650 UV/Vis spectrophotome-
ter (Perkin Elmer, Milan, Italy). Each sample was assessed 
in duplicate wells, in two experiments. The concentration 
of total IgE in each sample was calculated by extrapola-
tion against the standard curve obtained by measuring 
samples of known concentration. The antibody levels 
(mean ± S.D.) were expressed in ng ml−1 (total Ig) or in 
optical density units (anti-d2 Ig).
Preparation of BALF and lung tissue homogenate
Post sacrifice, BALF was collected by gentle injection of 
ice-cold PBS (0.3  ml) into the trachea, three times. The 
fluid was centrifuged (1200g  ×  5  min at 4  °C) and the 
supernatant was harvested at −80 °C for further analysis 
of the cytokines level by ELISA.
Also tissue homogenate was prepared from one lobe 
of lung tissue to be used to measure cytokine levels. The 
lung tissue was placed into a microcentrifuge tube, snap-
frozen in liquid nitrogen and stored at −80 °C until fur-
ther analysis. The frozen lungs were thawed, transferred 
to different tubes on ice containing 1  ml of Protease 
Inhibitor Cocktail (Sigma Aldrich, Milan, Italy). The lung 
tissues were homogenized at 4 °C with gentle MACS Dis-
sociator Miltenyi Biotec, Bologna, Italy). Lung homoge-
nates were centrifuged at 9000×g for 10  min at 4  °C. 
Supernatants were transferred to clean microcentrifuge 
tubes, frozen on dry ice for storage and thawed on ice for 
analysis. Total protein concentrations in the lung tissue 
homogenates were determined using a BCA kit (Sigma 
Aldrich). Lung tissue homogenates were diluted with 
buffer to a final protein concentration of 500 μg ml−1.
Cytokine levels determination in BALF and in lung tissue 
homogenate
Cytokines, namely IL-1β, IL-2, IL-4, IL-6, IL-10, INF-γ 
and TNF-α, were analyzed in BALF samples and lung tis-
sue homogenate supernatants by multiplex ELISA assay 
based on a fluorimetric method (Searchlight, Aushon 
Biosystem, MA, USA). Each sample (50  µl out of 1  ml 
for BALF or 500 µg ml−1 total protein for homogenate) 
was assessed in duplicate and the concentration of each 
cytokine was calculated by extrapolation against the 
standard curves obtained by measuring cytokine samples 
of known concentration using the Cirasoft™ Analyst soft-
ware (Aushon Biosystem). The level of IL-13 was deter-
mined by colorimetric ELISA using a commercial kit 
(Peprotech, DBA, Milan, Italy) according to the manu-
facturer’s instructions. Data are expressed as referred to 
1 ml of BALF or 500 µg total protein homogenate.
Histochemical analysis of the lung
The lungs were inflated and fixed with 10  % buffered 
formalin after collection of BALF. Sample were embed-
ded in paraffin and then sectioned. To ensure systematic 
uniform and random sampling, lungs were cut transver-
sally, to the trachea, into 2.0 mm thick parallel slabs with 
a random position of the first cut in first 2  mm of the 
lung, resulting in 5–8 slabs for lungs. The slabs were then 
embedded cut surface down and sections were stained 
with hematoxylin and eosin (BioOptica, Milan, Italy) for 
detecting inflammatory cell infiltrates. Briefly, images of 
three random sections within the left lung proximal to 
the main stem bronchus were acquired under the optical 
microscope Upright Nikon Microphot SA) at 200×  and 
400× magnification, photographed with the Nikon DXM 
120 color camera (Nikon Instruments, Melville, NY) and 
analyzed with the Act-1 software.
Evaluation of T regulatory cells frequency in spleen
Single cells suspensions of spleens were prepared by 
squeezing through 70  µm strainers (BD Labware) and, 
after erythrocytes osmotic lysis with Hybri-MaxTM 
(Sigma-Aldrich), were stained for flow cytometry analy-
sis using LIVE/DEAD® Fixable Aqua Stain (Thermofisher 
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Scientific, Milan, Italy), anti-CD4-FITC, anti-CD25-
APC and anti-FoxP3-PE of the Mouse Treg detection kit 
(Miltenyi Biotec), according to manufacturer instruction. 
FACS analyses were performed using a FACSCanto II and 
the data analyzed using FACSDiva Software 6.0 (BD Bio-
sciences). Single-stained and “fluorescence minus one” 
(FMO) samples were used as a compensation and analy-
sis controls. The following gating hierarchy was applied: 
cell debris were excluded by setting a first gate in a FL-2 
vs FL-3 (mock channel) dot plot; second, a forward light 
scatter/side light scatter (FSC/SSC) gate was applied on 
lympho-monocytes; third, a gate on CD4+ T cells was set 
and the percentage of Foxp3+CD25+  T cells within this 
population was determined. For each sample, twenty-
thousand events were acquired within the lymphocytes 
gate. Experiments were performed in duplicate.
Immunohistochemical detection of FoxP3+ cells 
and CD3+ cells in the lung
For immunoistochemistry, slides were deparaffinized 
and incubated with the following primary antibodies: 
CD3 (AB828, Rabbit anti-Human, Abcam, Milan, Italy) 
or FoxP3 (14 5773-82, Rat anti-Mouse, eBioscience, CA, 
USA) followed by the appropriate biotinylated second-
ary antibody (Jackson ImmunoResearch Laboratories, 
Milan, Italy). Immunoreactive antigens were detected 
using Streptavidin Peroxidase (Thermo Scientific-Lab 
Vision Corporation, CA, USA) and DAB Chromogen 
System (Dako Corporation, CA, USA) or Vulcan Fast Red 
Chromogen System (Biocare Medical, CA-USA). After 
chromogen incubation, slides were counterstained in 
Hematoxylin (BioOptica, Milan, Italy) and images were 
acquired by Leica DMRD optical microscope (Leica, 
United Kingdom). The rate of Treg cells was measured 
using a semiquantitative method and expressed as the 
number of FoxP3+ cell counts divided by the CD3+ cells 
scoring in five visual fields from different areas (sections): 
1 was attributed to samples with null or rare CD3+ cells, 
score 2 corresponded to some positive cells and score 3 
was given to samples with numerous positive cells.
Differential cell counts in the BALF
BALF was performed by gentle injection of ice-cold PBS 
(0.3 ml) into the trachea, three times. The collected fluids 
were centrifuged (1200g × 5 min at 4 °C) and the cellular 
pellet was recovered for differential cell count. The cells 
were immobilized onto glass slides by cytospin prepara-
tion and, after air dry fixation, were stained with hema-
toxylin and eosin (both from BioOptica, Milan, Italy). A 
total of 300 total cells were counted in each slide using 
a hematocytometer. The percentage of macrophages, 
lymphocytes/mononuclear cells, eosinophils and neu-
trophils was determined by microscopic observation 
according to standard morphological criteria under 400× 
magnification.
Statistical analysis
Values are expressed as mean ± SD. GraphPad Software 
6.0 (Prism) was used for statistical analysis. Unpaired 
Student t test was used to determine differences between 
two groups. One-way analysis of variance (ANOVA) with 
Bonferroni correction was used for multiple groups com-
parison. The p value less than 0.05 was considered statis-
tically significant (*p < 0.05, **p < 0.01, ***p < 0.001).
Results
Immunoglobulin levels in the serum
After sensitization, IgE levels were significantly higher in 
the group of mice only sensitized and not treated com-
pared with the naïve group (not sensitized, not treated): 
either total (+64 %, p < 0.01) (Fig. 1a) and anti-d2 specific 
IgE (+95 %, p < 0.01) (Fig. 1b).
Decrease of anti-d2-IgE was observed in all treated 
mice compared to sham group (not shown). Instead, 
only d2-OID + VD3 treatment induced the most signifi-
cant increase of d2-specific IgG2a levels; more precisely, 
IgG2a level for this group was significantly higher than 
that measured in the sham- and allergoid-treated groups 
(+55 %, p < 0.01 vs both) and for the VD3-treated group 
(p < 0.05) (Fig. 2).
Cytokine levels in lung homogenate and BAL fluid
Similar modifications were measured in the BAL fluid 
and lung homogenate for all the cytokines tested and 
only those relative to the first are described as follow.
The level of IL-4 was significantly lower after d2-OID 
(p  <  0.05 vs sham) or VD3 (p  <  0.05 vs sham) treat-
ment, and even less in the mice who received the com-
bined administration d2-OID + VD3 (p < 0.01 vs sham; 
p  <  0.05 vs d2-OID and VD3) (Fig.  3a). All treatments 
seem to produce a slight decrease in IL-13 level, but only 
the d2-OID + VD3 treatment was associated with a sig-
nificant modification (p  <  0.01 vs sham and p  <  0.05 vs 
d2-OID treatments) (Fig.  3b). A significant increase 
of IL-10 was observed for all treatments (showing the 
trend: sham  <  d2-OID  <  VD3  <  d2-OID  +  VD3); the 
latter produced the highest and most significant varia-
tion compared with each of the other three treatments 
(p  <  0.001 vs sham, p  <  0.01 vs d2-OID and p  <  0.5 vs 
VD3) (Fig.  3c). INF-γ increased in the groups of mice 
VD3 and d2-OID  +  VD3, but such change reached the 
significance (p  =  0.05) only in the group of mice that 
received the combined one (Fig. 3d). TNF-α significantly 
decreased for the all groups of mice, but the change 
reached the highest significance for the d2-OID +  VD3 
group (p < 0.01) (not shown). IL-6 level showed a general 
Page 5 of 10Petrarca et al. Clin Mol Allergy  (2016) 14:7 
trend of reduction, that was significant only for d2-OID-
VD3-treated mice (p  <  0.05) (not shown). For better 
understanding, all statistical analysis data are summa-
rized in Table 1.
Determination of T regulatory cells
In the spleen, the frequency of CD4+CD25+FoxP3+ cells 
assessed by FACS was significantly higher in all groups 
of treatment, compared with the sham group, although 
at different extent: the sole d2-OID treatment induced 
a limited increase Tregs (p < 0.05 vs sham), whereas the 
VD3 and d2-OID + VD3 groups showed a more evident 
and comparable change (p < 0.01 vs sham and p < 0.05 vs 
d2-OID, for both) (Fig. 4).
In the lung, the frequency of CD3+ T cells expressing 
the T regulatory cell marker FoxP3+ assessed by histo-
chemical analysis showed Foxp3+/CD3+ cells ratio is 
significantly higher in mice treated with d2-OID + VD3, 
compared to all groups: by 84  % compared with sham 
treated mice (p < 0.001), by 55 % compared with d2-OID-
treated mice (p < 0.01) and by 34 % compared with VD3-
treated mice (p  <  0.01). Increase in the abundance of 
Tregs was also associated with the other two treatments, 
although these differences were found less significant 
(p < 0.05 vs sham, for both) (Fig. 5).
BALF eosinophilia
Sensitization and challenge with Der p 2 significantly 
increased the frequency of BALF eosinophils in the 
sham-treated group compared with the naive group 
(not shown). The d2-OID treatment alone reduced (not 
significantly) the eosinophils abundance, whereas these 
inflammatory cells resulted significantly reduced in the 
VD3 alone group (p = 0.02 vs sham) and in mice treated 
by the combination d2-OID + VD3 (p = 0.01 vs sham). 
Moreover, the d2-OID + VD3 treatment was associated 
with the highest decrease, although at the limit of signifi-
cance, compared with the d2-OID treatment (p =  0.02) 
and the VD3 treatment (p = 0.051) (Fig. 6).
Fig. 1 Evaluation of the allergic sensitization state in mice. Detection of total and anti-d2 specific serum IgE to evaluate the occurrence of allergic 
sensitization in mice. The mice were sensitized by 2 i.p. with 1 µg of recombinant d2, and the level of IgE in serum was measured 1 week after the 
last i.p. Significantly higher total IgE (a) and d2-specific IgE (b) levels are found in serum of sensitized mice compared with naïve mice. Values are 
expressed as mean ± SD (n = 4). **p < 0.01 compared with naive mice
Fig. 2 Serum levels of d2-specific antibodies. Specific antibodies 
levels in serum were measured by ELISA 48 h after the last HDM 
aerosol challenge, to determine the effect of different treatments on 
the humoral response. d2-specific IgG2a level was most significantly 
increased in the d2-OID + VD3 group compared to sham- and 
d2-OID-treated mice (p < 0.01). Values are expressed as mean ± SD 
(n = 12). *p < 0.05; **p < 0.01
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Discussion
In our study, we investigated whether VD3, as an adjuvant 
for AIT, would be efficacious when administered in com-
bination with a low dose of antigen which, if taken alone, 
had no power to restore a non-pathological immune 
response to the native allergenic protein.
We found that VD3 is clearly able to enhance the 
effects of AIT with allergoid in a mouse model of aller-
gic asthma to dermatophagoides. The main finding of the 
study was the modulation of the local allergic inflamma-
tion in the lung obtained by the VD3-adjuvated allergoid 
AIT. In particular, it induced an increase in Tregs in the 
lung and a decrease in BALF eosinophils along with a 
Th1/Th2 shift: increase of d2-specific IgG2a antibodies, 
interferon-γ and IL-10 parallel to a reduction of IL-4 and 
IL-13. These changes were statistically significant when 
compared to sham and d2-OID treated mice, showing the 
effectiveness of VD3 as adjuvant for AIT in restoring the 
immune tolerance against the sensitizing allergen. Actu-
ally in literature there are demonstrations that the biolog-
ically active form of VD3 is able of modulating the innate 
and adaptive immune response [7–9]. VD3 was shown to 
induce a non-specific up-regulation of IL-10 and TGF-β 
[14] and of Tregs also in an experimental autoimmune 
disease model [20].
Also in our experiments VD3 was able to induce an 
increase in Tregs, particularly in the spleen where there 
was no significant differences in the increase in regula-
tory T lymphocytes between VD3 and adjuvated allergoid 
vaccine treated mice, in both cases significantly higher 
than sham and allergoid treated mice. By contrast, in 
the lung Tregs frequency increases significantly only in 
d2-OID + VD3 treated mice (Table 1). It seems that aller-
goid +  VD3 co-administration confers specificity to the 
Fig. 3 Treatment-induced modulation of cytokines’ levels in BALF. The levels of IL-4, IL-13, IL-10, INF-γ in BALF were measured by ELISA. The con-
ventional low dose IT with d2-OID or the sole VD3 administration induced decrease of IL-4 (a) and increase in IL-10 (c) and no change in the level of 
IL-13 and IFN-γ. Only the association d2-OID + VD3 produced the highest modification of these cytokines, well-matched with the resolution of the 
allergic inflammation, induction of tolerance and immune deviation: in fact, IL-4 (a) and IL-13 (b), were significantly lower and IL-10 (c) and IFN-γ (d) 
were significantly higher, compared with all the other groups. Values are expressed as mean ± SD (n = 12). *p < 0.05, **p < 0.01, ***p < 0.001
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VD3 adjuvant action: the Tregs abundance was similar 
for the two groups treated with VD3 or allergoid + VD3 
in the periphery, whereas, only the latter treatment pro-
duced the highest accumulation of Tregs exactly in the 
lung. This could be obtained through a homing driven by 
chemokine receptors expressed on their cell surface [26]. 
Moreover, the allergen-specific TcR of Tregs might have 
played a role in their localization in the inflamed lung 
as the inhaled allergen could be presented by endothe-
lial and parenchymal cells allowing trans-endothelial 
migration and tissue retention [27]. In this way the AIT 
approach is the only one able to increment locally the 
Table 1 Significance of  variations of  the parameters 
amongst the experimental groups
*p < 0.05, **p < 0.01, ***p < 0.001
Vs D2‑OID VD3 D2‑OID + VD3
D2-specific IgG2a (serum)
 Sham n.s. * **
 D2-OID * **
 VD3 *
IL-4 (BALF/lung homogenate)
 Sham * * **
 D2-OID n.s. *
 VD3 *
IL-13 (BALF/lung homogenate)
 Sham n.s n.s. **
 D2-OID n.s. *
 VD3 n.s.
IL-10 (BALF/lung homogenate)
 Sham * ** ***
 D2-OID * **
 VD3 *
IFN-γ (BALF/lung homogenate)
 Sham n.s. n.s. *
 D2-OID n.s. n.s.
 VD3 n.s.
TNF-α (BALF/lung homogenate)
 Sham * * **
 D2-OID n.s. n.s.
 VD3 n.s.
IL-6 (BALF/lung homogenate)
 Sham n.s. n.s. *
 D2-OID n.s. n.s.
 VD3 n.s.
Treg (FoxP3+ CD25+  % of CD4+, spleen)
 Sham * ** **
 D2-OID * *
 VD3 n.s
Treg (FoxP3:CD3, lung)
 Sham * * ***
 D2-OID n.s. **
 VD3 **
Eosinophils (lung)
 sham n.s. P = 0.02 (0.01)**
 D2-OID (0.05)* P = 0.02
 VD3 P = 0.051
Fig. 4 Frequency of Tregs in spleen cells. Flow cytometry data show-
ing the percentage of FoxP3+CD25+ cells on gated CD4+ cells of 
total spleen cells. The d2-OID treatment produced an increase of this 
subpopulation of regulatory cells (p < 0.05 vs sham) but not as high 
as for the other groups of treatment. Either VD3 or d2-OID administra-
tion induced the highest increase in FoxP3+CD25+ cells, compared 
with sham (p < 0.01, for both groups) or d2-OID (p < 0.05, for both 
groups). Values are expressed as mean ± SD (n = 12). *p < 0.05 and 
**p < 0.01
Fig. 5 Abundance of T regulatory cells in lung tissue. A significant 
comparable increase in FoxP3+:CD3+ cells ratio was induced by 
d2-OID and VD3 treatments (p < 0.05 vs sham); the combination treat-
ment d2-OID + VD3 was even more efficacious in inducing such an 
increase (p < 0.001 vs sham, p < 0.01 vs d2-OID and VD3 treatments) 
Values are expressed as mean ± SD (n = 7). ***p < 0.001 **p < 0.01. 
*p < 0.05
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Treg cell population and represents the best choice for 
allergy management. Other strategies for the develop-
ment of anti-allergic compounds are focusing on the 
inhibition of the migration of inflammatory cells in the 
lung, acting on the CCR-ligand interaction [28]. How-
ever, these kinds of approaches might have important 
side effects since they block homing receptors that are 
non specific for a certain cell type but are shared amongst 
different ones. Therefore, we believe that the strategy of 
incrementing the allergen-specific Tregs population into 
the lung of allergic subjects might be more effective in 
the extinction of allergic inflammation with reduced risk 
of detrimental outcomes.
Furthermore, a reduction of the eosinophils accumula-
tion was found in the lungs of both VD3 alone and the 
VD3-adjuvated AIT treated mice, significantly higher 
than allergoid-treated mice. Again, VD3 + allergoid asso-
ciation appeared to be more efficacious than VD3 alone. 
Although these data may be affected by bias due to semi-
quantitative evaluation, it is plausible that the effects of 
the low dose of allergoid used in our experiments are 
misted up by the effects of the VD3 and that a further 
reduction of eosinophils might be achieved with a higher 
dose of allergoid. Coherently with the highest accumula-
tion of FoxP3+ T cells in the lung of VD3 adjuvated AIT 
treated mice we observed a significant decrease of Th2 
and regulatory citokines in BALF.
Moreover, it is expected that the VD3 + d2-OID asso-
ciation may have a longer lasting effect compared to 
other treatments, as suggested by the induction of the 
highest levels of IFN-γ in the lung. In fact, the induction 
of this cytokine, a typical product of Th1 cells, confirms 
the occurrence of the so called Th2/Th1 shift needed for 
a successful AIT [1]. A similar plan to obtain long-term 
effect of allergen-specific immunotherapy in a murine 
model of type I allergy (towards OVA) has been described 
by Heine and colleagues [15]. Differently, they used as 
comparison terms deficient VD3 dose and, as therapy, the 
precursor of VD3, to mimic the condition characterizing 
people living at certain latitudes, and to avoid ipercalce-
mia-associated toxicity. They conclude that VD3 correc-
tion helps the efficacy of AIT [15].
In our settings, we mimic the other condition of a nor-
mal level of serum VD3, essential for the correct ongoing 
of a plethora of immunological and biological processes, 
and the possible effect of a non-toxic supplementation on 
AIT.
Future developments of the present study could include 
the demonstration that the combined administration of 
VD3 and allergoid in an AIT setting can act in a specific 
manner and that the allergoid ensures the tolerogenic/
inhibitory action limitedly to the Th2 allergen-specific 
cells and that such specificity promotes the accrual of 
Tregs at the inflammation sites. The specificity of the 
observed Tregs-mediated response in vivo and the effec-
tive suppression of the airway inflammation will be 
assessed with functional studies in vitro (inhibition stud-
ies) and in vivo (pulmonary function).
Conclusions
The concept to use vitamin D3 as an adjuvant immu-
nomodulant factor in allergy treatment has been 
explored in this study. The most relevant finding regards 
the accumulation of Tregs in the lung associated with 
the treatment of sensitized and airway-challenged mice 
by immunotherapy based on 2d-OID  +  VD3 adminis-
tration. This effect appears to be allergen-driven and 
allergen-specific. This is a promising result for improv-
ing the current AIT. In particular, it is envisaged that the 
covalent linking of VD3, directly or indirectly, to the aller-
goid would allow to achieve highest local concentration 
of both compounds [21]. Practically, the addition of VD3 
to a conventional AIT protocol would allow the reduc-
tion of allergoid dose needed and therefore, the produc-
tion costs. Moreover, this study shows that important 
immunomodulatory effects can be achieved by the oral 
administration. This modality of treatment might favour 
the management of the therapy by the patients and their 
adherence.
This represents a further and particularly inter-
esting development of the described approach as it 
might enhance the efficacy of the observed immune 
Fig. 6 Eosinophils abundance in BALF. The frequency of eosino-
phils cells in total BALF cells showed a trend in diminution follow-
ing d2-OID treatment, but it was significantly decreased only with 
the treatments VD3 (p = 0.02 vs sham and p = 0.05 vs d2-OID) 
and d2-OID + VD3 (p = 0.01 compared with sham and p = 0.02 vs 
d2-OID). The d2-OID + VD3 induced a further decrease in eosinophils 
at the limit of significance, compared to VD3 (p = 0.051). Values are 
expressed as mean ± SD (n = 7)
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modulation. However, first, confirmative experiments on 
the specificity and functional role of the Treg population 
is needed.
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